Nicholas Investment Partners LP Takes Position in Kymera Therapeutics, Inc. $KYMR

Nicholas Investment Partners LP bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 54,569 shares of the company’s stock, valued at approximately $6,257,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. US Bancorp DE grew its holdings in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after buying an additional 235 shares during the period. Cetera Investment Advisers increased its stake in shares of Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after buying an additional 252 shares during the period. Finally, Larson Financial Group LLC raised its holdings in Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after buying an additional 287 shares during the last quarter.

Kymera Therapeutics Trading Up 1.0%

Shares of Kymera Therapeutics stock opened at $121.05 on Tuesday. The company’s fifty day simple moving average is $110.13 and its two-hundred day simple moving average is $92.46. The company has a market cap of $10.07 billion, a P/E ratio of -37.36 and a beta of 1.95. Kymera Therapeutics, Inc. has a 12-month low of $39.84 and a 12-month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same period in the prior year, the business earned ($0.95) EPS. The company’s revenue for the quarter was up 465.2% on a year-over-year basis. Analysts predict that Kymera Therapeutics, Inc. will post -3.75 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the sale, the director directly owned 472,267 shares of the company’s stock, valued at approximately $52,086,327.43. The trade was a 49.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,591,908 shares of company stock worth $386,532,863 over the last ninety days. Corporate insiders own 15.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Canaccord Genuity Group boosted their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Guggenheim increased their target price on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Truist Financial raised their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Barclays boosted their price target on Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $125.65.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.